Arbutus Biopharma Corp Payments to Acquire Other Investments
Arbutus Biopharma Corp (ABUS) reported Payments to Acquire Other Investments of $28.90 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2020-11-05
- 2020-09-30: Payments to Acquire Other Investments 9 month $28.90M.
- 2019-09-30: Payments to Acquire Other Investments 9 month $0.00.
| Period end | Payments to Acquire Other Investments 9 month |
|---|---|
| 2020-09-30 | $28.90M 10-Q · filed 2020-11-05 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |